Progress Report 2011

Mel Spigelman, Co-Chair

Mission

To accelerate the discovery and development of new tuberculosis treatments by bringing together all stakeholder perspectives, including those of the patients, in TB Drug Research and Development



- Resource Gateway
- Catalyst of Dialog and Exchange
- Dynamic and Expanding Network

WGND Organization Updates





Total members: **197**

up from 145 last year

Stop TB Partnership

WORKING GROUP ON NEW TB DRUGS

Major Initiatives


WGND Initiatives 2011
Website Enhancements
Events
PZA
Strategic Planning Meeting
Publications
Strategic Plan
Networking
CPTR
Stop TB Working Groups


WGND Initiatives 2012
Website Enhancements
Events
Biology Targets Meeting
Clinical Capacity
Quarterly Sub-Group Meetings
Publications
Blueprint
Networking
Host Targeting Taskforce
Community Engagement
Resource Mobilization

PIPELINE

Login/Register to add a Project

Download the PPT Slide

CLINICAL DEVELOPMENT

PRECLINICAL DEVELOPMENT

CPZEN-45
Caprazene nucleoside
Microbial Chemistry Research Foundation, Tokyo, Japan, Lilly TB Drug Discovery Initiative, NIAID, IDRI, Lilly, YourEncore

Quinolone DC-159a
Fluoroquinolone Antibiotics
Japan Anti-Tuberculosis Association, JATA, Daiichi-Sankyo Pharmaceutical Co.

SQ609
Dipiperidines
Sequella

SQ641
Capuramycins
Sequella

BTZ043 GLP
Benzothiazinones
New Medicines For Tuberculosis (NM4TB)

Q201-Novel anti-TB agent
Imidazopyridine
Quro Science, Inc.

PHASE I

AZD5847 NCE
Oxazolidinone
Astrazeneca

PHASE II

PA-824 REG NCE
Nitroimidazol-oxazine
TB Alliance

Novel Combinations/Regimens NCE
Nitroimidazol-oxazine, diarylquinoline, fluoroquinolone, Nicotinic acid derivative
TB Alliance

PNU-100480 NCE
Oxazolidinone
Pfizer

TMC207 (Bedaquiline) for MDR-TB NCE
Diarylquinoline
Tibotec BVBA

SQ109 NCE
Ethylenediamines
Sequella,NIH

TMC207(Bedaquiline) for DS-TB NCE
Diarylquinoline
TB Alliance, Janssen Pharmaceutica N.V.

OPC-67683 (Delamanid) NCE
Nitro-dihydro-imidazooxazole
Otsuka Pharmaceutical Co., Ltd.

Linezolid for MDR-TB
Oxazolidinones
TBTC, Pfizer

Rifapentine (TBTC study 29)
Rifamycin
CDC, Sanofi-aventis

PHASE III

Gatifloxacin
Fluoroquinolones
Information provided by WGND

Moxifloxacin for Drug-Sensitive TB
Fluoroquinolones
University College London

Rifapentine (TBTC Study 26)
Rifamycin
CDC, Sanofi-aventis

DISCOVERY PIPELINE

Login/Register to add a Project

Download the PPT Slide

HIT-TO-LEAD

Phenotypic Hit-to-Lead
University of Illinois, TB Alliance

M. tuberculosis Protein Kinase Inhibitors
Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles
Vertex Pharmaceuticals, Incorporated

Fungal metabolites
Mycosynthetix, University of Illinois at Chicago

Actinomycete metabolites
University of Illinois at Chicago, Myongji University

DNA metabolism
Novel structural class
AstraZeneca R and D Bangalore

Phenotypic hit to lead
Multiple novel structural classes
Lilly TB Drug Discovery Initiative

Novel hit-lead programs
Novel structural class
Lilly TB Drug Discovery Initative

Phenotype Hit-to-Lead
Novel structural classes
AstraZeneca R and D Bangalore

Combinatorial Biosynthetic Compounds
Shaw Environmental and University of Illinois at Chicago

Folate Biosynthesis Inhibitors
AstraZeneca, TB Alliance

Phenotypic Hit-to-Lead
GlaxoSmithKline, TB Alliance

Malate Synthase Inhibitors
GlaxoSmithKline , Texas A&M University, TB Alliance

Menaquinone Synthase Inhibitors
Colorado State University, TB Alliance

Inhibitors of Mycobacterium Tuberculosis Energy Metabolism
Various Classes
UPenn and TB Alliance

Inhibitors of isoprenoid biosynthesis
Lilly TB Drug Discovery Initiative

Protein Splicing Inhibitors
Boston Biomedical Research Institute

LEAD-OPTIMIZATION

Nitroimidazoles
Nitroimidazoles
TB Alliance, University of Auckland, University of Ilinois

Diarylquinolines
Diarylquinoline
TB Alliance, University of Auckland, Tibotec

Riminophenazines
Riminophenazines antibiotic
TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois

InhA Inhibitors
Novel structural class
GlaxoSmithKline, TB Alliance

LeuRS inhibitors
Oxaboroles
Anacor Pharmaceuticals

Mycobacterial Gyrase Inhibitors
Novel structural class
TB Alliance, GlaxoSmithKline

Pyrazinamide Analogs
Pyrazinamide/nicotinamide analogs
TB Alliance/Yonsei University

TL1 Inhibitors
Capuramycins
Sequella

MTopo
Novel structural class
AstraZeneca R and D Bangalore

GyrB Inhibitors
AstraZeneca , TB Alliance

SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis
Inorganic Compounds
FAPESP/Brazil

Spectinamides
Spectinomycin analogs
St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix

WORKING GROUP
ON NEW TB DRUGS

Please Join the conversation